Effectiveness of the autumn 2023 COVID-19 vaccine dose in hospital-based healthcare workers: results of the VEBIS healthcare worker vaccine effectiveness cohort study, seven European countries, season 2023/24

• Main Author: Savulescu, Camelia
• Publication Date: 2024
• Other Authors: Prats-Uribe, Albert, Brolin, Kim, Uusküla, Anneli, Bergin, Colm, Fleming, Catherine, Murri, Rita, Zvirbulis, Viesturs, Zavadska, Dace, Gaio, Vania, Popescu, Corneliu P., Hrisca, Raluca, Cisneros, Maria, Latorre-Millán, Miriam, Lohur, Liis, McGrath, Jonathan, Ferguson, Lauren, De Gaetano Donati, Katleen, Abolina, Ilze, Gravele, Dagne, Machado, Ausenda, Florescu, Simin-Aysel, Lazar, Mihaela, Subirats, Pilar, Clusa Cuesta, Laura, Sui, Jacklyn, Kenny, Claire, Santangelo, Rosaria, Krievins, Dainis, Barzdina, Elza Anna, Valadas Henriques, Camila, Kosa, Alma Gabriela, Pohrib, Saftica-Mariana, Muñoz-Almagro, Carmen, Milagro, Ana, Bacci, Sabrina, Nardone, Anthony, VEBIS HCW VE study group, Collaborators in VEBIS HCW study group
• Format: Article
• Language: eng
• Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
• Download full: http://hdl.handle.net/10400.18/10494
• topic: COVID-19; SARS-CoV-2; Vaccine effectiveness; Healthcare workers; Europe; Estados de Saúde e de Doença; Observação em Saúde e Vigilância

COVID-19 vaccination recommendations prioritise healthcare workers (HCWs), considering their exposure to severe acute respiratory coronavirus 2 (SARS-CoV-2) and their key role in the functioning of healthcare systems. In the European Union/European Economic Area (EU/EEA), HCWs were considered a priority for COVID-19 revaccination during the autumn 2023 campaign [1], and the World Health Organization (WHO) recommended revaccination of HCWs 12 months after their last dose [2]. Because the Omicron sub-lineage XBB.1.5 predominated in spring 2023, the COVID-19 vaccines were adapted to target this emerging strain, and the first XBB.1.5 vaccine was authorised for use in the EU/EEA in August 2023. Omicron BA.2.86/JN.1 emerged in the EU/EEA at the end of 2023, according to data available on the European Respiratory Virus Surveillance Summary (ERVISS) [3]. Evidence for COVID-19 vaccine recommendation in the HCW population remains scarce. Within the Vaccine Effectiveness, Burden and Impact (VEBIS) project, we aimed to measure the COVID-19 vaccine effectiveness (CVE) in HCWs, in the winter season 2023/24.